Comparative Pharmacology
Head-to-head clinical analysis: GENTAMICIN versus GVS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTAMICIN versus GVS.
GENTAMICIN vs GVS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis; bactericidal against gram-negative aerobes.
GVS is not a recognized drug. No mechanism of action available.
5-7 mg/kg/day IV or IM in divided doses every 8 hours; for serious infections, up to 5 mg/kg/day IV in 3 divided doses.
1 mg IV bolus every 3 minutes up to 3 doses as needed for status epilepticus; max total dose 3 mg.
None Documented
None Documented
2-3 hours in adults with normal renal function; prolonged to 24-48 hours in anuria; adjust dosing based on renal function.
Clinical Note
moderateGentamicin + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Gentamicin."
Clinical Note
moderateGentamicin + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Gentamicin."
Clinical Note
moderateGentamicin + Deslanoside
"The serum concentration of Deslanoside can be decreased when it is combined with Gentamicin."
Clinical Note
moderateGentamicin + Acetyldigitoxin
Terminal half-life: 3-5 hours in healthy adults; prolonged to 8-12 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (glomerular filtration): 90-95% unchanged in urine over 24 hours; biliary/fecal: <2%.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other.
Category D/X
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic
"The serum concentration of Acetyldigitoxin can be decreased when it is combined with Gentamicin."